SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

L3Harris Technologies, Inc. engages in the provision of defense and commercial technologies across the air, land, sea, space, and cyber domains. It operates through the following segments: Communication Systems, Integrated Mission Systems, Space and Airborne Systems, and Aerojet Rocketdyne. The Communication Systems segment enables warfighters across all domains with solutions critical to mission success even in the most contested environments. The Integrated Mission Systems segment focuses on the differentiated mission capabilities and prime systems integration for the air, land, and sea domains. The Space and Airborne Systems segment provides full mission solutions as a prime and subsystem integrator in the space, airborne, and cyber domains. The Aerojet Rocketdyne segment includes propulsion, power and armament products and systems to U.S. government, including the DoD, National Aeronautics and Space Administration (“NASA”) and major aerospace and defense prime contractors. The company was founded in 1890 and is headquartered in Melbourne, FL.

L3Harris Technologies Inc

L3Harris is trending following a $1 billion Pentagon investment in its missile business and an announced plan to spin off the unit as a standalone, publicly traded company in late 2026. While some investors view the spinoff as a strategic way to unlock value and scale manufacturing, the stock is seeing significant volatility as traders debate the long-term impact on the core business and current valuation.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Arista Networks is trending as investors exhibit strong confidence in the company's role as a critical networking infrastructure provider for AI data centers and hyperscaler cloud expansion. The stock is receiving attention due to its sustained technical momentum and positioning as a beneficiary of robust AI-related capital expenditure.

Amgen, Inc. is a biotechnology company, which engages in the discovery, development, manufacture, and marketing of human therapeutics. The company was founded by William K. Bowes, Jr., Franklin Pitcher Johnson, Jr., George B. Rathmann, and Joseph Rubinfeld on April 8, 1980 and is headquartered in Thousand Oaks, CA.

AMGEN Inc.

Amgen is trending due to a sharp sympathy sell-off triggered by a failed Phase 3 trial of a competitor's cholesterol drug, despite market commentary noting the company's distinct mechanism and robust underlying fundamentals. While some investors are concerned about potential read-through risks to its own pipeline, many traders view the price decline as an overreaction and a buying opportunity.

PIMCO Dynamic Income Fund is a non-diversified, closed-end management investment company. Its seeks current income as a primary objective and capital appreciation as a secondary objective. The company was founded on January 19, 2011 and is headquartered in New York, NY.

PIMCO Dynamic Income Fund

A prolonged selloff has pushed PDI to a rare discount to NAV, drawing attention to the funds sensitivity to rising long-term yields, leverage, and credit-market risks. Traders are split between viewing the discount and unchanged monthly distribution as a buying opportunity and fearing weakening coverage or a future distribution cut.

Global X Funds - Global X Dow 30 Covered Call ETF

Global X Dow 30 Covered Call ETF

The community discussion is fragmented, characterized by a mix of political commentary regarding the upcoming election cycle, speculation on geopolitical tensions in the Middle East, and varied technical analysis of broader market direction and inflation concerns.

Gilead Sciences, Inc. is a biopharmaceutical company, which engages in the research, development, and commercialization of medicines in areas of unmet medical need. The firm's primary areas of focus include human immunodeficiency virus, acquired immunodeficiency syndrome, liver diseases, hematology, oncology, and inflammation and respiratory diseases. It offers antiviral products under Harvoni, Genvoya, Epclusa, Truvada, Atripla, Descovy, Stribild, Viread, Odefsey, Complera/Eviplera, Sovaldi, and Vosevi brands. The company was founded by Michael L. Riordan on June 22, 1987 and is headquartered in Foster City, CA.

Gilead Sciences, Inc.

Gilead Sciences is trending due to community discussions regarding its acquisition strategy, specifically the $7.8 billion deal for Arcellx to bolster its CAR-T cell therapy pipeline. Traders are also actively analyzing the company's Q4 financial results, dividend increase, and competitive outlook for its HIV and oncology franchises.

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, including hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders such as Parkinson’s disease, metabolic disorders, including thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Abbvie Inc

AbbVie shares are trending as the company navigates the $10.9 billion acquisition of Apogee Therapeutics to bolster its immunology pipeline and continues to see strong performance from its core growth drivers, Skyrizi and Rinvoq. Investors are actively debating the company's valuation, dividend stability, and strategic M&A approach, while also monitoring competitive threats within its key therapeutic areas.

Frequency Electronics, Inc. engages in the design, development, and manufacture of precision time and frequency generation technology. It operates through the following business segments: FEI-NY and FEI-Zyfer. The FEI-NY segment provides precision time, frequency generation, and synchronization products and subsystems that are found on-board satellites, in ground-based communication stations, and imbedded in moving platforms. The FEI-Zyfer segment designs, develops, and manufactures products for precision time and frequency generation and synchronization, primarily incorporating GPS technology. The company was founded by Martin B. Bloch on August 25, 1961 and is headquartered in Uniondale, NY.

Frequency Electronics, Inc.

Frequency Electronics is trending following a significant post-earnings rally, with traders highlighting the company's strong funded backlog, record financial results, and its critical role in defense and aerospace sectors like the 'Golden Dome' missile defense program. The community remains largely bullish, noting the company's relatively small float and potential for future contract wins, though some participants express caution regarding market volatility and the impact of previous earnings reports on share price.

AstraZeneca Plc is a global, science-led biopharmaceutical company focused on the discovery, development, and commercialization of prescription medicines. Its portfolio spans oncology, rare diseases, and biopharmaceuticals, including cardiovascular, renal & metabolism, and respiratory & immunology. The company was founded in 1913 and is headquartered in Cambridge, the United Kingdom.

Astrazeneca plc

AstraZeneca PLC

AstraZeneca is trending following a failed late-stage clinical trial of its breast cancer drug Etcamah, which missed its primary endpoint for progression-free survival in first-line patients. While traders remain bearish due to recurring pipeline setbacks, some investors view the price drop as an overreaction, highlighting the company's long-term oncology potential.

ON Semiconductor Corp. engages in the provision of intelligent power and sensing solutions with a primary focus on automotive and industrial markets. It operates through the following segments: Power Solutions Group (PSG), Analog and Mixed-Signal Group (AMG), and Intelligent Sensing Group (ISG). The PSG segment offers discrete, module, and integrated semiconductor products that perform multiple application functions, including power switching, signal conditioning, and circuit protection. The AMG segment designs and develops analog, mixed-signal, power management integrated circuits, sensor interface devices, power conversion, signal chain, and voltage regulation devices. The ISG focuses on the design and development of complementary metal oxide semiconductor image sensors, image signal processors, single photon detectors, including silicon photomultipliers, single photon avalanche diode arrays, and short-wavelength infrared products, as well as actuator drivers for autofocus and image stabilization. The company was founded on July 4, 1999 and is headquartered in Scottsdale, AZ.

ON Semiconductor Corp.

ON Semiconductor is trending as traders analyze the impact of the company's $7 billion all-stock acquisition of Synaptics, with sentiment split between concerns over equity dilution and optimism regarding long-term expansion into physical AI and edge computing. While the stock faced sharp selling pressure following the announcement, some investors view the pullback as a potential entry point for long-term growth.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Kura Oncology Pivots Diabetes Strategy Into $50 Million Subsidiary

Kura Oncology launches Caspian Therapeutics with $50 million financing to advance menin inhibitor for diabetes and cardiometabolic diseases.read more...

Kura Oncology Names Jennifer Fulk CFO

(RTTNews) - Kura Oncology, Inc. (KURA), on Tuesday appointed Jennifer Fulk as Chief Financial Officer, effective September 8...

KURA Stock Gains 37.6% in a Month: Here's What You Need to Know

Kura's rising Komzifti sales, promising AML data and pipeline catalysts boost investor confidence and fuel KURA's gains.

Kura Oncology (KURA) Upgraded to Buy: What Does It Mean for the Stock?

Kura Oncology (KURA) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Oncology Stocks to Add to Your Portfolio as Cancer Care Evolves

Oncology innovation is driving new treatment options, with Iovance, Merit Medical and Kura advancing cancer-focused therapies and technologies.

 Company News for Aug 26, 2026

Companies in The News Are: DKS,KURA,NVTS,WMT

KURA Stock Hits Fresh 52-Week High As CEO Buys More Shares — Retail Wonders If Wilson Is Following Moderna CEO’s Playbook

Equity

According to a filing with the SEC, Kura President and CEO Troy Edward Wilson bought 100,000 shares of common stock on August 24 for about $1.24 million in total.


Kura Oncology CEO Buys 100,000 Shares for $1.2 Million. Does This Large Buy Bode Well for Shares in 2026?

Key PointsThe President and CEO acquired ~100,000 shares at $12.39 per share for a total transaction value of $1.2 million...

Futures Bounce As Brent Drops Under $90 On Renewed Iran Optimism

Futures Bounce As Brent Drops Under $90 On Renewed Iran Optimism

 Global stocks rose as?chipmakers?rebounded, with falling bond?yields?adding support to risek sentiment after Brent crude slid below $90 a barrel, down more than 3% after a New York times reports?that "evacuated...

Stocks making the biggest moves premarket: Dick's Sporting Goods, Advanced Micro Devices, Kura Oncology & more

These are the stocks posting the largest moves in early trading...

Kura Oncology, Inc. operates as a clinical-stage biopharmaceutical company, which engages in the research and development of medicines for the treatment of cancer. Its pipeline includes Tipifarnib, which is a Farnesyl transferase inhibitor for HRAS Mutant Solid Tumors, Chronic Myelomonocytic Leukemia, KO-947, which is an ERK inhibitor for MAPK Pathway Tumors, and KO-539, which is a Menin MLL inhibitor for acute leukemias. The company was founded by Troy E. Wilson, Yi Liu, Pingda Ren and Antonio Gualberto on August 22, 2014 and is headquartered in San Diego, CA.

Kura Oncology Inc

Neutral Sentiment

President Trump has promised to issue a $5,000 "dividend" check to every adult American citizen if the Republican Party wins control of both the House and the Senate in the upcoming midterm elections, though the proposal would require congressional approval and follows his earlier $2,000 tariff-dividend plan, which stalled after the Supreme Court struck down much of his tariff authority. Do you think the $5,000 dividend check actually happens? Vote and explain your reasoning in the comments.

Trump has pledged a $5,000 &quot;dividend&quot; check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Stocktwits

Trump has pledged a $5,000 "dividend" check to every adult American citizen if Republicans win control of both the House and Senate in the midterms. Do you think it actually happens?

Feed

News

Sentiment

Earnings

Fundamentals

Info

KURA Kura Oncology Inc

Fundamentals

Latest KURA News